References
- MalvezziMBertuccioPLeviFLa VecchiaCNegriEEuropean cancer mortality predictions for the year 2014Ann Oncol20142581650165624759568
- World Health OrganizationGLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012 Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspxAccessed November 17, 2016
- LepageCCapocacciaRHacklMSurvival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5Eur J Cancer Epub952015
- National Cancer InstituteSurveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Pancreas Cancer2016 Available from: http://seer.cancer.gov/statfacts/html/pancreas.html
- RyanDPHongTSBardeesyNPancreatic adenocarcinomaN Engl J Med20143712221402141
- DucreuxMCuhnaASCaramellaCCancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v56v6826314780
- NCCN Clinical Practice Guidelines in OncologyPancreatic Adenocarcinoma. V12016 Available from: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAccessed November 17, 2016
- Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
- ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
- MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
- GoldsteinDEl-MaraghiRHHammelPnab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialJ Natl Cancer Inst20151072dju41325638248
- TaberneroJChioreanEGInfanteJRPrognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerOncologist201520214315025582141
- VogelARömmler-ZehrerJLiJSMcGovernDRomanoAStahlMEfficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)BMC Cancer201616181727769210
- ChioreanEGVon HoffDDTaberneroJSecond-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerBr J Cancer2016115218819427351217
- GiordanoGFebbraroAMilellaMImpact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line nab-paclitaxel (nab-P) + gemcitabine (G): an Italian multicentre real life experienceJ Clin Oncol (Meeting Abstracts)201634Suppl abstr 4124